Full textPdf 

http://doi.org/10.31288/oftalmolzh201236872

ULTRASTRUCTURAL CHANGES OF THE CHOROID AND RETINA OF RABBITS IN INTRAVITREAL INJECTION OF SELECTIVE AND NONSELECTIVE INHIBITORS OF GROWTH FACTORS OF THE VASCULAR ENDOTHELIUM

N. E. Dumbrova, A. R. Korol, I. O. Nasinnyk, T. B. Kustrin

Odessa, Ukraine

The authors investigated structural changes of the choroid and retina of rabbits after intravitreal injection se¬lective and nonselective anti-VEGF. It has been revealed that pegaptanib sodium and ranibizumab do not damage photoreceptors cells. However, pegaptanib sodium leads to ultrastructural damages of the ganglion cells and pigment epithelium of the retina.

References

1.Ameri H. The effects of intravitreous bevacizumab on retinal neovascular membrane and capillaries in rabbits / H. Ameri, G. J. Chader, J. G. Kim [et al.] // Invest Ophthalmol Vis Sci. — 2007. — Vol.48 . — P.5708- 5714.
Crossref

2.Avci B. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits / B. Avci, R. Avci, U. U. Inan [et al.] // Invest Ophthalmol Vis Sci. — 2009. — Vol.50. — P.3438- 3446.
Crossref

3.Congdon N. Causes and prevalence of visual impairment among adults in the United States / N. Congdon, B. O'Colmain, C. C. Klaver [et al.] // Arch Ophthalmol. — 2004. — Vol.122. — P.477- 485.
Crossref

4.D'Amore P. A. Mechanisms of retinal and choroidal neo-vascularization / P. A. D'Amore // Invest Ophthalmol Vis Sci. — 1994. — Vol.35. — P.3974- 3979.

5.Dib E. Subretinal bevacizumab detection after intravitreous injection in rabbits / E. Dib, M. Maria, I. M. Longo-Maugeri [et al.] // Invest Ophthalmol Vis Sci. — 2008. — Vol.49. — P.1097- 1100.
Crossref

6.Gragoudas E. S. Pegaptanib for neovascular age-related macular degeneration / E. S. Gragoudas, A. P. Adamis, E. T. Cunningham [et al.] // N Engl J Med. — 2004. Vol.351. — P.2805- 2816.
Crossref

7.Grossniklaus   H.   E.   Choroidal neovascularization / H. E. Grossniklaus, W. R. Green // Am J Ophthalmol. — 2004. — Vol.137. — P. 496- 503.
Crossref

8.Heiduschka P. Penetration of Bevacizumab through the retina after intravitreal injection in the monkey / P. Heiduschka, H. Fietz, S. Hofmeister [et al.] // Invest Ophthalmol Vis Sci. — 2007. — Vol.48. — P.2814-2823.
Crossref

9.Inan U. U. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes / U. U. Inan, B. Avci, T. Kusbeci [et al.] // Invest Ophthalmol Vis Sci. — 2007. —Vol.48. — P.1773-1781.
Crossref

10.Ishida S. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization І S. Ishida, T. Usui, K. Yamashiro [et al.] ІІ J Exp Med. - 2003. - Vol. 198. - P. 483- 489.
Crossref

11.Kaempf S. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture І S. Kaempf, S. Johnen, A. K. Salz [et al.] ІІ Invest Ophthalmol Vis Sci. - 2008. Vol.49. -P.3164-3170.
Crossref

12.Kepmen J. H. The prevalence of diabetic retinopa-thy among adults in the United States І J. H. Kepmen,B. J. O'Colmain, M. C. Leske [et al.] ІІ Arch Ophthalmol. - 2004. - Vol.122. - P.552- 563.
Crossref

13.ЮЄЙПЄГ A. K. Comparison of bevacizumab, ranibizumab and pegaptanib in vitro efficiency and possible additional pathways І A. K. Klettner, J. Roider ІІ Invest Ophthalmol Vis Sci. - 2008. - Vol.49. - P.4523- 4527.
Crossref

14.Kourlas H. Pegaptanib sodium for the treatment of neo-vascular age-related macular degeneration: a review IH. Kourlas, D. S. Schiller Ц Clin Ther. - 2006. -Vol.28. - P.36- 44.
Crossref

15.Leung D. W. Vascular endothelial growth factor is a secreted angiogenicmitogen І D. W. Leung, G. Cachianes, W. J. Kuang [et al.] Ц Science. -  1989. - Vol.246. - P.1306-1309.
Crossref

16.Lowe J. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo І J. Lowe, J. Araujo, J. Yang [et al.] ІІ Exp Eye Res. - 2007. - Vol.85. - Vol. 425- 430.
Crossref

17.Manzano R. P. Testing intravitreal toxicity of bevacizumab (Avastin) І R. P. Manzano, G. A. Peyman, P. Khan [et al.] IIRetina. - 2006. - Vol.26. - P. 257- 261.
Crossref

18.Ng E. W. M. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease І E. W. M. Ng, D. T. Shima, P. Calias [et al.] Ц Nat Rev Drug Discov. -  2006. -Vol.5. - P.123- 132.
Crossref

19.Petere S. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab І S. Peters, P. Heiduschka, S. Julien [et al.] Ц Am J Ophthalmol. - 2007. -Vol.143. - P.995- 1002.
Crossref

20.Saxe S. J. Ultrastructural features ofsurgically excised sub-retinalneovascular membranes in the ocular histoplasmo-sissyndrome І S. J.Saxe, H. E. Grossniklaus, P. F. Lopez [et al.] ІІ Arch Ophthalmol. - 1993. - Vol.111. - P. 88- 95.
Crossref

21.Shaba J. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin) І J. Shahar, R. L. Avery, G. Heilweil [et al.] ІІ Retina. - 2006. - Vol.26. - P.262- 269.
Crossref

22.Spitzeг M. S. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells І M. S. Spitzer, E. Yoeruek, A. Sierra [et al.] Ц Graefes Arch Clin Exp Ophthalmol. - 2007. - Vol. 245. - P. 1837-1842.
Crossref

23.ТШІЄГ S. Toxicity testing of the VEGF inhibitors bevacizumab,ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage І S. Thaler, M. Fiedorowicz, T. Jr. Choragiewicz [et al.] ІІ Acta Ophthalmol. - 2010. Vol.88. - P.170-176
Crossref

24.Yandiev Y. Intravitreal avastin does not induce pathologi¬cal changes in the pig retina І Y. Yandiev, M. Francke, A. Reichenbach [et al.] Ц ARVO Meeting - 2008. Abstracts 49. - P.5580.